Abstract
The article provides information about a study that studies the features of drug treatment of patients with Parkinson's disease among the population of the capital of Azerbaijan Republic- Baku. The study is based on data from 703 patients with Parkinson's disease diagnosed in outpatient clinics in Baku by the beginning of 2019. In the treatment of Parkinson's disease, all modern treatment options were used (Dopamine receptor agonists, Levodopa drugs, Antixolinergik drugs, COMT inhibitors, NMDA receptor antagonists, etc.). According to the study results, the standard approach is used in the treatment of Parkinson's disease in Baku, but in most cases, polytherapy is preferred (59.2±1.9 per 100 patients). In terms of frequency of use in treating Parkinson's disease, the first two places are occupied by dopamine precursors (63.2±1.8 per 100 patients) and dopadecarboxylase inhibitors (59.2±1.9 per 100 patients), respectively. Among the drugs used for the treatment of Parkinson's disease, Nakom (28.2±1.7 per 100 patients) and its combination with Cyclodol (10.4±1.2 per 100 patients) and Akineton (10.1±1.1 per 100 patients) prevail. Monotherapy is carried out only with Pronoran and Cyclodol (17.1±1.4 and 10.7±1.2 per 100 patients, respectively).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
